Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Marinus Pharma CS (NQ: MRNS )

13.20 USD +0.47 (+3.69%)
Streaming Delayed Price Updated: 4:01 PM EST, Jan 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Marinus Pharma CS

< Previous 1 2 3 4 5 6 Next >
Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in CDKL5 Deficiency Disorder
Marinus received a positive response from the FDA on sufficiency of Marigold Study data to support filing of NDA for the use of ganaxolone in CDD. 
From Business Wire News Releases
Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference
Marinus management will participate in the 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect 2021 Conference. 
From Business Wire News Releases
Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index
Marinus Pharmaceuticals announced it has been selected for inclusion in the Nasdaq Biotechnology Index (NBI). 
From Business Wire News Releases
Marinus Pharmaceuticals Announces Pricing of $70 Million Public Offering of Common Stock
Marinus Pharmaceuticals announces the pricing of an underwritten public offering of 5 million shares of its common stock for gross proceeds of $70MM. 
From Business Wire News Releases
Marinus Pharmaceuticals Announces Underwritten Public Offering of Common Stock
Marinus Pharmaceuticals announces an underwritten public offering of its common stock. 
From Business Wire News Releases
Marinus Pharmaceuticals Provides Additional Ganaxolone Data During Scientific Exhibit at AES2020 Virtual Annual Meeting and Provides Corporate Update
Marinus Pharmaceuticals will provide additional ganaxolone data during #AES2020 Scientific Exhibit. 
From Business Wire News Releases
Marinus Launches Expanded Access Program for Ganaxolone Treatment in CDKL5 Deficiency Disorder
Marinus Pharmaceuticals launches an expanded access program that offers ganaxolone to patients with CDKL5 deficiency disorder. 
From Business Wire News Releases
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Marinus Pharmaceuticals announced the grant of inducement awards to two new employees. 
From Business Wire News Releases
Marinus Pharmaceuticals to Host Virtual Investor Event at AES On December 7, 2020
Marinus Pharmaceuticals will host a webinar with updates on its programs in status epilepticus, CDD, and TSC at #AES2020. 
From Business Wire News Releases
Marinus Pharmaceuticals Announces Four Presentations on Ganaxolone at AES2020 Virtual Annual Meeting
Marinus Pharma. to present updates and data from its trials in CDKL5 and refractory status epileptics at American Epilepsy Society's conference. 
From Business Wire News Releases
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Marinus Pharmaceuticals announced the grant of inducement awards to two new employees. 
From Business Wire News Releases
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results
Marinus Pharmaceuticals provides a business update following its "milestone" third quarter. 
From Business Wire News Releases
Marinus Pharmaceuticals Appoints Christy Shafer as Chief Commercial Officer
Marinus Pharmaceuticals appoints Christy Shafer as Chief Commercial Officer. Shafer will report to CEO Dr. Scott Braunstein, and comes from Alexion. 
From Business Wire News Releases
WaterMill Asset Management Sends Letter to Ziopharm Oncology Shareholders
WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of... 
From Business Wire News Releases
Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2020 Financial Results on November 9, 2020
Marinus Pharmaceuticals will announce its financial results for the third quarter on November 9, 2020 following the close of market. 
From Business Wire News Releases
Marinus Pharmaceuticals Participates in Upcoming Investor Healthcare Conferences
Marinus Pharmaceuticals announced that company management will participate in a number of investor healthcare conferences from late Oct. through Nov. 
From Business Wire News Releases
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Marinus Pharmaceuticals announced the grant of inducement awards to 11 new employees. 
From Business Wire News Releases
Thinking about trading options or stock in Moderna, Marinus Pharmaceuticals, Roku, Microsoft, or Costco?
InvestorsObserver issues critical PriceWatch Alerts for MRNA, MRNS, ROKU, MSFT, and COST. 
From PR Newswire
Marinus Provides Corporate Update on Phase 3 RAISE Trial in Status Epilepticus (SE)
Marinus Pharmaceuticals has satisfied the FDA's protocol-specific questions for its Phase 3 trial in RSE and announces VPs, Clinical Development. 
From Business Wire News Releases
Marinus Announces One-for-Four Reverse Stock Split
Marinus Pharmaceuticals announced that it will effect a one-for-four reverse stock split of its common stock at 5:00 pm ET today. 
From Business Wire News Releases
Thinking about buying stock in Marinus Pharmaceuticals, Fiat Chrysler, Lithium Americas, Xeris Pharmaceuticals, or Nokia?
InvestorsObserver issues critical PriceWatch Alerts for MRNS, FCAU, LAC, XERS, and NOK. 
From PR Newswire
Ganaxolone Achieves Primary Endpoint in Phase 3 Trial for CDKL5 Deficiency Disorder (CDD), a Rare Form of Genetic Epilepsy
Marinus Pharmaceuticals achieves primary endpoint in Phase 3 trial evaluating the use of oral ganaxolone in patients with CDKL5 deficiency disorder. 
From Business Wire News Releases
Marinus Awarded BARDA Contract to Develop IV Ganaxolone for Treatment of Refractory Status Epilepticus Caused by Nerve Agent Exposure
Marinus Pharmaceuticals, Inc. has entered into a 5-year development contract with BARDA to support the development of IV ganaxolone. 
From Business Wire News Releases
Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences
Marinus Pharmaceuticals' management will present at three investor conferences the week of September 14. 
From Business Wire News Releases
Thinking about buying stock in Coca-Cola, Just Energy, Marinus Pharma, Gevo, or Nutanix?
InvestorsObserver issues critical PriceWatch Alerts for KO, JE, MRNS, GEVO, and NTNX. 
From PR Newswire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Marinus Pharmaceuticals announced the grant of inducement awards to seven new employees. 
From Business Wire News Releases
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
Marinus Pharmaceuticals provides an update on its clinical development activities and reports financial results for the second quarter of 2020. 
From Business Wire News Releases
Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Ganaxolone for the Treatment of CDKL5 Deficiency Disorder (CDD)
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced today that the U.S. Food and... 
From Business Wire News Releases
Marinus Pharmaceuticals Appoints Charles Austin to Board of Directors
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) has appointed former Johnson & Johnson Corporate VP Charles "Chuck" Austin to its Board of Directors. 
From Business Wire News Releases
Marinus Pharmaceuticals Provides Pipeline Update
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.